A Comparison of the Pharmacokinetics and Pharmacodynamics of Pregabalin and Gabapentin

被引:0
|
作者
Howard N. Bockbrader
David Wesche
Raymond Miller
Sunny Chapel
Nancy Janiczek
Paula Burger
机构
[1] Pfizer Global Research & Development,
[2] Pfizer Global Research & Development,undefined
来源
Clinical Pharmacokinetics | 2010年 / 49卷
关键词
Neuropathic Pain; Gabapentin; Pregabalin; Postherpetic Neuralgia; Pain Score Reduction;
D O I
暂无
中图分类号
学科分类号
摘要
Pregabalin and gabapentin share a similar mechanism of action, inhibiting calcium influx and subsequent release of excitatory neurotransmitters; however, the compounds differ in their pharmacokinetic and pharmacodynamic characteristics. Gabapentin is absorbed slowly after oral administration, with maximum plasma concentrations attained within 3–4 hours. Orally administered gabapentin exhibits saturable absorption — a nonlinear (zero-order) process — making its pharmacokinetics less predictable. Plasma concentrations of gabapentin do not increase proportionally with increasing dose. In contrast, orally administered pregabalin is absorbed more rapidly, with maximum plasma concentrations attained within 1 hour. Absorption is linear (first order), with plasma concentrations increasing proportionately with increasing dose. The absolute bioavailability of gabapentin drops from 60% to 33% as the dosage increases from 900 to 3600 mg/day, while the absolute bioavailability of pregabalin remains at <-90% irrespective ofthe dosage. Both drugs can be given without regard to meals. Neither drug binds to plasma proteins. Neither drug is metabolized by nor inhibits hepatic enzymes that are responsible for the metabolism of other drugs. Both drugs are excreted renally, with elimination half-lives of approximately 6 hours.
引用
收藏
页码:661 / 669
页数:8
相关论文
共 50 条
  • [31] Comparison of the Effectiveness of Duloxetine versus Pregabalin/Gabapentin for Treatment of Diabetic Peripheral Neuropathy
    Shabana, C. R.
    Oommen, Shamlin M.
    Varghese, Sherin John
    Sabin, P. S.
    Geetha, K.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 582 - 583
  • [32] Gabapentin and Pregabalin for the Treatment of Anxiety Disorders
    Greenblatt, H. Karl
    Greenblatt, David J.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2018, 7 (03): : 228 - 232
  • [33] Pregabalin or morphine and gabapentin for neuropathic pain
    Doggrell, SA
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (14) : 2535 - 2539
  • [34] An Insight into Gabapentin and Pregabalin in Scottish Prisoners
    Deeb, Shaza
    Wylie, Fiona M.
    Torrance, Hazel J.
    Scott, Karen S.
    JOURNAL OF ANALYTICAL TOXICOLOGY, 2020, 44 (05) : 504 - 513
  • [35] Gabapentin and pregabalin for the treatment of chronic pruritus
    Matsuda, Kazuki M.
    Sharma, Divya
    Schonfeld, Ariel R.
    Kwatra, Shawn G.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 75 (03) : 619 - +
  • [36] A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban
    Frost, Charles
    Song, Yan
    Barrett, Yu Chen
    Wang, Jessie
    Pursley, Janice
    Boyd, Rebecca A.
    LaCreta, Frank
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2014, 6 : 179 - 187
  • [37] Comparison of Everolimus Pharmacokinetics and Pharmacodynamics between Ethnicities.
    Taber, D.
    Belk, L.
    Pilch, N.
    McGillicuddy, J.
    Bratton, C.
    Chavin, K.
    Baliga, P.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 470 - 471
  • [38] THE PHARMACOKINETICS OF NOMIFENSINE - COMPARISON OF PHARMACOKINETICS AND PHARMACODYNAMICS USING COMPUTER PHARMACO-EEG
    SALETU, B
    GRUNBERGER, J
    LINZMAYER, L
    TAEUBER, K
    INTERNATIONAL PHARMACOPSYCHIATRY, 1982, 17 : 43 - 72
  • [39] GABAPENTIN AND PREGABALIN TOLERABILITY IN FACIAL PAIN PATIENTS
    Besi, E.
    Kyrtsos, M.
    Boniface, D.
    Zakrzewska, J. M.
    CEPHALALGIA, 2016, 36 : 91 - 92
  • [40] How addictive are gabapentin and pregabalin? A systematic review
    Bonnet, U.
    Scherbaum, N.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 (12) : 1185 - 1215